Good agreement between physician and self-reported hormone therapy data in a case-control study.
Standard
Good agreement between physician and self-reported hormone therapy data in a case-control study. / Kropp, S; Terboven, T; Hedicke, J; Mutschelknauss, E; Slanger, T; Braendle, Ludwig-Wilhelm; Berger, Jürgen; Chang-Claude, J; Flesch-Janys, Dieter.
In: J CLIN EPIDEMIOL, Vol. 60, No. 12, 12, 2007, p. 1280-1287.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Good agreement between physician and self-reported hormone therapy data in a case-control study.
AU - Kropp, S
AU - Terboven, T
AU - Hedicke, J
AU - Mutschelknauss, E
AU - Slanger, T
AU - Braendle, Ludwig-Wilhelm
AU - Berger, Jürgen
AU - Chang-Claude, J
AU - Flesch-Janys, Dieter
PY - 2007
Y1 - 2007
N2 - OBJECTIVE: In a population-based case-control study examining the effects of postmenopausal hormone therapy (HT) on breast cancer risk, the authors conducted a validation study comparing prescription data from gynecologists with self-reports. STUDY DESIGN AND SETTING: The study was conducted in the Rhein-Neckar and Hamburg regions of Germany from 2002 to 2005. A total of 224 cases and 225 controls, stratified by region, age, and hormone use were randomly selected for the validation study. RESULTS: For ever/never use 88.2% agreement was seen, and agreement for ever/never use by type of HT was 80.6%, 80.3%, and 90.5% for mono-estrogen, cyclical combined, and continuous combined therapy, respectively. The intraclass correlation coefficient (ICC) for duration of use was high, 0.82 (95% confidence interval [CI]: 0.77, 0.85), as were the ICCs for age at first and last use, 0.88 (95% CI: 0.85, 0.91) and 0.98 (95% CI: 0.97, 0.98). Despite the exceptionally high number of different HT prescriptions available in Germany, comparison of exact brand name resulted in perfect agreement for 50.2% of participants, partial agreement for 29.3%, and no agreement for 20.7%. In general, agreement was not differential by disease status. CONCLUSION: Overall, the self-reported HT of the study participants corresponded well with physicians' reports.
AB - OBJECTIVE: In a population-based case-control study examining the effects of postmenopausal hormone therapy (HT) on breast cancer risk, the authors conducted a validation study comparing prescription data from gynecologists with self-reports. STUDY DESIGN AND SETTING: The study was conducted in the Rhein-Neckar and Hamburg regions of Germany from 2002 to 2005. A total of 224 cases and 225 controls, stratified by region, age, and hormone use were randomly selected for the validation study. RESULTS: For ever/never use 88.2% agreement was seen, and agreement for ever/never use by type of HT was 80.6%, 80.3%, and 90.5% for mono-estrogen, cyclical combined, and continuous combined therapy, respectively. The intraclass correlation coefficient (ICC) for duration of use was high, 0.82 (95% confidence interval [CI]: 0.77, 0.85), as were the ICCs for age at first and last use, 0.88 (95% CI: 0.85, 0.91) and 0.98 (95% CI: 0.97, 0.98). Despite the exceptionally high number of different HT prescriptions available in Germany, comparison of exact brand name resulted in perfect agreement for 50.2% of participants, partial agreement for 29.3%, and no agreement for 20.7%. In general, agreement was not differential by disease status. CONCLUSION: Overall, the self-reported HT of the study participants corresponded well with physicians' reports.
M3 - SCORING: Zeitschriftenaufsatz
VL - 60
SP - 1280
EP - 1287
JO - J CLIN EPIDEMIOL
JF - J CLIN EPIDEMIOL
SN - 0895-4356
IS - 12
M1 - 12
ER -
